Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Current Deferred Revenue (2016 - 2018)

Cardiff Oncology (CRDF) has disclosed Current Deferred Revenue for 4 consecutive years, with $486636.0 as the latest value for Q4 2018.

  • Quarterly Current Deferred Revenue rose 45.51% to $486636.0 in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $486636.0 through Dec 2018, up 45.51% year-over-year, with the annual reading at $486636.0 for FY2018, 45.51% up from the prior year.
  • Current Deferred Revenue hit $486636.0 in Q4 2018 for Cardiff Oncology, up from $472251.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $486636.0 in Q4 2018 to a low of $30614.0 in Q4 2015.
  • Historically, Current Deferred Revenue has averaged $313552.3 across 4 years, with a median of $298213.0 in 2017.
  • Biggest five-year swings in Current Deferred Revenue: soared 831.75% in 2016 and later increased 6.62% in 2017.
  • Year by year, Current Deferred Revenue stood at $30614.0 in 2015, then skyrocketed by 831.75% to $285246.0 in 2016, then increased by 17.24% to $334424.0 in 2017, then skyrocketed by 45.51% to $486636.0 in 2018.
  • Business Quant data shows Current Deferred Revenue for CRDF at $486636.0 in Q4 2018, $472251.0 in Q3 2018, and $349565.0 in Q2 2018.